Avantax Planning Partners Inc. Grows Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Avantax Planning Partners Inc. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,571 shares of the medical research company’s stock after purchasing an additional 282 shares during the period. Avantax Planning Partners Inc.’s holdings in Thermo Fisher Scientific were worth $6,142,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Northwest Financial Advisors acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Raleigh Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $49,000. Finally, Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $51,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TMO. HSBC lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Finally, Raymond James increased their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of TMO traded down $5.77 during midday trading on Thursday, hitting $585.03. The company had a trading volume of 1,170,031 shares, compared to its average volume of 1,507,049. The company’s 50 day moving average price is $576.44 and its 200 day moving average price is $545.71. The stock has a market cap of $223.32 billion, a price-to-earnings ratio of 37.90, a PEG ratio of 2.75 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 32,000 shares of company stock valued at $18,486,980 in the last ninety days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.